Production (Stage)
BioAge Labs, Inc.
BIOA
$3.98
$0.030.76%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 19.18% | -- | -- | -- | -- |
| Gross Profit | -3.62% | -- | -- | -- | -- |
| SG&A Expenses | 54.44% | 32.00% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.53% | 61.56% | -- | -- | -- |
| Operating Income | -64.62% | -61.56% | -- | -- | -- |
| Income Before Tax | -8.03% | -11.36% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.03% | -11.36% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.03% | -11.36% | -- | -- | -- |
| EBIT | -64.62% | -61.56% | -- | -- | -- |
| EBITDA | -64.81% | -61.75% | -- | -- | -- |
| EPS Basic | 60.36% | 39.78% | -- | -- | -- |
| Normalized Basic EPS | 52.96% | 28.94% | -- | -- | -- |
| EPS Diluted | 60.36% | 39.78% | -- | -- | -- |
| Normalized Diluted EPS | 52.96% | 28.94% | -- | -- | -- |
| Average Basic Shares Outstanding | 1,051.67% | 541.04% | -- | -- | -- |
| Average Diluted Shares Outstanding | 1,051.67% | 541.04% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |